Seizure reduction with fluoxetine in an adult woman with Dravet syndrome

Kimford J. Meador *

Department of Neurology & Neurological Sciences, Stanford University School of Medicine, 300 Pasteur Drive (Room A343), Stanford, CA 94305-5235, USA. Tel.: +1 650 725 6648; fax: +1 650 498 6326.
E-mail address: kmeador@stanford.edu.

1. Introduction

Dravet syndrome is an epileptic encephalopathy, which was first described in 1978 [1,2]. It is a spectrum of conditions with variability in severity and manifestations but usually with catastrophic consequences [3].

1.1. Etiology

Mutations in the voltage-gated sodium-channel gene alpha subunit (SCN1A) were discovered in an epileptic syndrome called genetic epilepsy with febrile seizures plus (GEF+) including some patients with severe myoclonic epilepsy of infancy (SMEI) in GEF+ families [4–6]. Later, new SCN1A mutations were found in nonfamilial SMEI [7]; these mutations were de novo and more severe than those associated with GEF+ [8]. Because some patients with the epileptic encephalopathy do not exhibit myoclonus, the disorder is now known as Dravet syndrome. Approximately 90% of patients with Dravet syndrome have de novo mutations, about 75% of patients with Dravet syndrome have mutations in the gene encoding SCN1A, and over 300 SCN1A mutations on chromosome 2q24 have been found [8,9]. Other genes implicated in Dravet syndrome include PCDH19, GABRG2, and SCN1B [8].

Animal models exhibit the characteristic temperature/age dependent seizures seen in humans, and there is a 50% reduction in sodium current in heterozygous SCN1A mutations [10]. Since the SCN1A protein is expressed predominately in GABAergic interneurons as opposed to excitatory pyramidal neurons, Dravet syndrome is considered a genetic dysfunction of inhibitory interneurons [8,11].

1.2. Clinical manifestations

Onset is typically in the first year of life in a previously healthy infant who experiences a seizure associated with fever, vaccination, or illness [8]. Initial seizures are generalized or hemiclonic, and the first seizure may be status epilepticus. Over the next few years, other seizure types usually develop, which may include atypical absence, focal (with impaired consciousness), myoclonic, atonic, and tonic seizures and convulsive or nonconvulsive status. Seizures may be triggered by fever, fatigue, photosensitivity, or excitement [2]. By the age of 2 years, developmental delay is usually apparent. Deterioration occurs from ages 1 to 4 years with the occurrence of psychomotor, behavioral, and gait abnormalities [2]. After age 5, convulsive seizures usually decrease and may occur mainly in sleep [2]. Cognitive and behavioral problems stabilize and may improve to a degree, but at least half of patients remain severely impaired. Magnetic resonance imaging shows only diffuse atrophy, and EEG may have diffuse slowing with generalized spike and polyspike and wave discharges and/or multifocal epileptiform discharges [8]. The seizures are typically medically resistant. Carbamazepine, lamotrigine,
and phenytoin may exacerbate seizures. Valproate, benzodiazepines, stiripentol, and topiramate are the most effective antiepileptic drugs. However, seizures persist into adulthood [8]. Mortality is about 15% by adulthood in patients with Dravet syndrome [8].

2. Case report

The case report described here was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). DL is a 27-year-old woman with Dravet syndrome. She has a confirmed SCN1A mutation with deletion of 1 bp of C nucleotide position 1650, codon 550. Her first seizure occurred at age 4 months after a diphtheria–pertussis–tetanus vaccination without fever; it consisted of some left-arm jerks. She had her first convulsion at age 6 months and her first episode of status epilepticus at age 3 years after which her development was noted to be distinctly abnormal. Over the years, DL suffered from multiple seizure types including generalized tonic–clonic, focal (with impaired consciousness), and myoclonic seizures and atomic drop attacks. Seizures were increased with fever and later in a catamnial pattern. Her seizures failed to improve with multiple antiepileptic drugs including carbamazepine, clonazepam, clorazepate, felbamate, lamotrigine, levetiracetam, lorazepam, phenobarbital, phenytoin, primidone, retigabine, stiripentol, tiagabine, topiramate, valproate, and zonisamide. A strict ketogenic diet and vagal nerve stimulation also failed to improve her seizures.

Magnetic resonance imaging showed only diffuse atrophy. Electroencephalograms and video-EEGs revealed multifocal spikes and polyspikes interictally, and recorded generalized tonic–clonic seizures had ictal onssets with diffuse decrement. Her genetic diagnosis was made at age 21 years.

In late July 2009, DL was started on fluoxetine 20 mg daily in an attempt to reduce stereotypic behaviors characterized as vigorous back-and-forth head shaking, which was sometimes associated with facial grimace and raising of her legs into a flexed position. These behaviors occurred multiple times per day but did not occur out of sleep. The family thought that they could sometimes be interrupted with distraction. At the time, DL’s medications included felbamate (2400 mg/day), levetiracetam (1000 mg/day; higher dosages were ineffective and caused behavioral problems), diazepam PR PRN, lorazepam PO PRN, fexofenadine PRN, medroxyprogesterone, polyethylene glycol, melatonin, and multivitamins. Her last prior medication change had been tapering and then stopping of stiripentol in May 2009, which did not cause any worsening of her seizures on withdrawal.

Fluoxetine therapy was effective in markedly reducing the stereotypic behaviors but, surprisingly, it was also associated with a marked reduction in seizures. In the months preceding fluoxetine in that year, DL had an average of 8–10 seizures per month. In the remaining months of that year after initiation of fluoxetine, DL’s seizure frequency dropped to 3–4 per month, and the seizures were less severe. This reduction in seizures has been maintained, and the seizures even improved over subsequent years without any other changes in antiepileptic drugs. Her seizures were predominantly generalized tonic–clonic seizures in recent years. Now, they are rare, brief, and usually nocturnal. Her behavior and cognitive function have also had modest improvements (see Table 1 for annual seizure rates).

3. Discussion

The observed reduction in seizure could be due to the natural reduction in seizures in patients with Dravet syndrome that occurs with aging [2]. However, fluoxetine was begun at age 24 years, and the seizure reduction typically occurs before that age. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). Recently, a preliminary study showed remarkable efficacy for fenfluramine in reducing seizures in patients with Dravet syndrome [12]. Fenfluramine increases serotonin levels via inhibition of serotonin uptake and disruption of serotonin of vesicular storage [12].

Several investigations suggest that serotonin possesses antiepileptic properties [13]. For example, SSRIs increase extracellular 5-HT, which inhibits focal and generalized seizures in several animal models of generalized epilepsy and focal epilepsy [14–16]. Activation of 5HT1A receptors can result in membrane hyperpolarizing associated with increased potassium conductance [17,18], and stimulation of 5HT1A receptors in the thalamus can increase GABA release, reducing excitation in an animal model [19]. Further, 5HT2C agonists prevent seizures, and 5HT2C antagonists lower seizure threshold in both focal and generalized models of epilepsy [20]. In humans, three open trials with SSRIs have also suggested possible antiepileptic effects [21–23]. Specifically in regard to fluoxetine, an open trial of 17 patients with focal epilepsy followed over a mean of 14 months reported seizure freedom in 6 patients and decreased seizure frequency by 30% in the other 11 patients [23]. Thus, the observed response to fluoxetine in DL may be due to its serotonin effects.

4. Conclusions

This case report suggests that the SSRI fluoxetine may have efficacy in reducing seizures in Dravet syndrome. The finding is consistent with the preliminary findings of antiseizure efficacy for fenfluramine, another agent with serotonergic effects. In addition, several investigations in animals suggest that serotonin agents possess antiepileptic properties. Given the potential adverse cardiac effects of fenfluramine, randomized clinical trials of other serotonergic agents like fluoxetine should be considered in patients with Dravet syndrome and other types of epilepsy.

Acknowledgments

The author would like to thank the family of DL for their assistance. This work was supported by the Patient-Centered Outcomes Research Institute (527) and the National Institutes of Health (NS038455).

Conflicts of interest

Dr. Meador reports no financial conflicts of interest in relation to this publication.

References

[1] Dravet C. Les épilepsies graves de l’enfant. Vie Med 1978;8:543–8.
[2] Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol 2013;111:627–33.
[3] Guerrini R. Dravet syndrome: the main issues. Eur J Paediatr Neurol 2012;16(Suppl. 1):S1–4.
[4] Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus: a genetic disorder with heterogeneous clinical phenotypes. Brain 1997;120:479–90.
[5] Wallace RH, Scheffer IE, Barnett S, Richards M, Dibbens L, Desai RR, et al. Neuronal sodium-channel alpha 1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet 2001:68:859–65.
[6] Singh R, Andermann E, Whitehouse WP, Harvey AS, Keene DL, Seni MH, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEF+? Epilepsia 2001;42:837–44.
[7] Claei L, Del-Favero J, Cuelmans B, Lagaia L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001:68:1327–32.

Table 1

| Year | Total # of seizures |
|------|---------------------|
| 2007 | 116                 |
| 2008 | 95                  |
| 2009 | 93                  |
| 2010 | 37                  |
| 2011 | 16                  |
| 2012 | 12                  |
| 2013 | 4                   |
[8] Scheffer IE. Diagnosis and long-term course of Dravet syndrome. Eur J Paediatr Neurol 2012;16(Suppl. 1):S5–8.

[9] Lossin C. A catalog of SCN1A variants. Brain Dev 2009;31:114–30.

[10] Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006;9:1142–9.

[11] Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007;27(22):5903–14.

[12] Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012;53(7):1131–9.

[13] Hamid H1, Kanner AM. Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs? Epilepsy Behav 2013;26(3):261–5.

[14] Richerson GB, Buchanan GF. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011;52(Suppl. 1):28–38.

[15] Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. J Neurochem 2007;100(4):857–73.

[16] Igelstrom KM. Preclinical antiepileptic actions of selective serotonin reuptake inhibitors – implications for clinical trial design. Epilepsia 2012;53(4):596–605.

[17] Beck SG, Choi KC. 5-Hydroxytryptamine hyperpolarizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neurosci Lett 1991;133:93–6.

[18] Okuhara DY, Beck SG. 5-HT1A receptor linked to inward-rectifying potassium current in hippocampal CA3 pyramidal cells. J Neurophysiol 1994;71:2161–7.

[19] Graf M, Jakus R, Kantor S, Levis G, Bagdy G. Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett 2004;359(1–2):45–8.

[20] Hoyer D, Fozard JR, Hartig PR. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine. Pharmacol Rev 1994;46(2):157–203.

[21] Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 2003;12(5):316–8.

[22] Specchio LM, Iudice A, Specchio N, La Neve A, Spinelli A, Galli R, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004;27(3):133–6.

[23] Favale E, Mainardi P, Rubino V, Lunardi G, Albano C. The anticonvulsant effect of fluoxetine in humans. Neurology 1995;45:1926.